Systematic review links GLP-1 drugs to better headache and vision outcomes in IIH
Nine studies suggest GLP-1 drugs may ease headache and protect vision in idiopathic intracranial hypertension, but the evidence is mostly retrospective and no large randomized trial has been done.
A systematic review published October 7, 2025 in The Journal of Headache and Pain concludes that GLP-1 receptor agonists may improve headache, vision and weight in people with idiopathic intracranial hypertension, or IIH, while reducing reliance on acetazolamide and surgery [1].
IIH is a neurologic condition defined by elevated pressure inside the skull and swelling of the optic nerve, called papilledema, usually in women of reproductive age with obesity [1]. Its incidence has risen along with obesity rates, reaching about 22 per 100,000 in young women with obesity [1]. Symptoms include chronic headache and pulsatile tinnitus, and untreated IIH can lead to permanent visual impairment or blindness [1].
The review searched MEDLINE, Scopus and Web of Science through June 15, 2025 and followed PRISMA 2020 guidelines [1]. It included nine clinical studies — one randomized controlled trial and eight observational studies — of adults with IIH who received GLP-1 receptor agonists [1].
Across those studies, GLP-1 receptor agonist use "was consistently associated with improvements in headache frequency, weight reduction, and reduced need for acetazolamide or surgical interventions" [1]. In the single randomized trial, which involved 16 patients with IIH, exenatide significantly lowered intracranial pressure within hours of administration, and no serious safety concerns were reported [1].
Several studies reported resolution of papilledema and a lower risk of visual deterioration [1]. Cognitive function either improved or remained stable [1]. Adverse effects were mostly mild gastrointestinal symptoms, and no serious safety concerns emerged [1].
First-line IIH treatment is weight loss plus carbonic anhydrase inhibitors such as acetazolamide, which reduce cerebrospinal fluid production [1]. Even a modest 6–10% weight reduction can significantly improve IIH outcomes, but achieving and maintaining that loss through diet and lifestyle is difficult, and acetazolamide often gives only partial headache relief while causing dose-limiting side effects such as paresthesia, fatigue, nausea and cognitive impairment [1]. Topiramate, diuretics such as furosemide and other off-label pressure-lowering drugs have limited efficacy [1]. When medication fails, surgery may be needed, including venous sinus stenting, optic nerve sheath fenestration and cerebrospinal fluid shunting [1].
The authors say their interpretation is limited because most of the data are retrospective and potentially overlapping, with minimal randomized evidence [1]. They conclude that GLP-1 receptor agonists "show promise as a disease-modifying therapy for IIH" with benefits that may go beyond weight loss, and that the consistency of findings justifies a shift toward well-powered phase 3 randomized controlled trials [1].
The review does not detail which specific GLP-1 drugs were used in each study, at what doses, or for how long. No large randomized trial of semaglutide in IIH has reported results.
Why it matters for patients
IIH has an unmet need for medical therapies that lower intracranial pressure and ease symptoms without adding new problems [1]. The review suggests GLP-1 receptor agonists might act on both weight and headache, and might reduce the use of acetazolamide or surgery [1]. That prospect matters to patients who cannot tolerate acetazolamide or topiramate, or who are facing a surgical procedure.
The evidence is still preliminary. Nine studies is a small base, only one was randomized, and that trial enrolled 16 patients. Most of the data came from retrospective records that may include the same patients more than once [1]. The review's conclusion is a call for stronger research, not a recommendation for how IIH should be treated.
GLP-1 receptor agonists are established treatments for type 2 diabetes and obesity [1]. The review does not address whether any of them are approved for IIH, and the studies it describes were not designed to establish dosing.
What happens next
The review calls for well-powered phase 3 randomized controlled trials to validate the preliminary findings and define optimal treatment strategies [1]. It does not name specific planned trials or give start or completion dates, so the timing of any phase 3 program in IIH has not been reported [1].
Images from the sources
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.